226 related articles for article (PubMed ID: 20519625)
1. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
Maniar A; Zhang X; Lin W; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Blood; 2010 Sep; 116(10):1726-33. PubMed ID: 20519625
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
3. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
Cancer Immunol Immunother; 2013 Aug; 62(8):1359-68. PubMed ID: 23689729
[TBL] [Abstract][Full Text] [Related]
5. Searching for "signal 2": costimulation requirements of γδ T cells.
Ribot JC; debarros A; Silva-Santos B
Cell Mol Life Sci; 2011 Jul; 68(14):2345-55. PubMed ID: 21541698
[TBL] [Abstract][Full Text] [Related]
6. Histamine modulates γδ-T lymphocyte migration and cytotoxicity, via Gi and Gs protein-coupled signalling pathways.
Truta-Feles K; Lagadari M; Lehmann K; Berod L; Cubillos S; Piehler S; Herouy Y; Barz D; Kamradt T; Maghazachi A; Norgauer J
Br J Pharmacol; 2010 Nov; 161(6):1291-300. PubMed ID: 20977468
[TBL] [Abstract][Full Text] [Related]
7. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.
von Lilienfeld-Toal M; Nattermann J; Feldmann G; Sievers E; Frank S; Strehl J; Schmidt-Wolf IG
Clin Exp Immunol; 2006 Jun; 144(3):528-33. PubMed ID: 16734623
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.
Kim YJ; Han MK; Broxmeyer HE
Blood; 2008 Feb; 111(3):1378-86. PubMed ID: 18024793
[TBL] [Abstract][Full Text] [Related]
9. THEMIS2 Impairs Antitumor Activity of NK Cells by Suppressing Activating NK Receptor Signaling.
Deborah EA; Nabekura T; Shibuya K; Shibuya A
J Immunol; 2024 Jun; 212(11):1819-1828. PubMed ID: 38619282
[TBL] [Abstract][Full Text] [Related]
10. Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
Fowler D; Barisa M; Southern A; Nattress C; Hawkins E; Vassalou E; Kanouta A; Counsell J; Rota E; Vlckova P; Draper B; De Mooij T; Farkas A; Brezovjakova H; Baker AT; Scotlandi K; Manara MC; Tape C; Chester K; Anderson J; Fisher J
Sci Transl Med; 2024 May; 16(749):eadg9814. PubMed ID: 38809963
[TBL] [Abstract][Full Text] [Related]
11. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
[TBL] [Abstract][Full Text] [Related]
12. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
Pereboeva L; Harkins L; Wong S; Lamb LS
Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
[TBL] [Abstract][Full Text] [Related]
13. Bayesian approach to model CD137 signaling in human M. tuberculosis in vitro responses.
Fernández Do Porto DA; Auzmendi J; Peña D; García VE; Moffatt L
PLoS One; 2013; 8(2):e55987. PubMed ID: 23437083
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism.
Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Adv Sci (Weinh); 2021 Nov; 8(21):e2101029. PubMed ID: 34486239
[TBL] [Abstract][Full Text] [Related]
15. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
Kühnöl C; Herbarth M; Föll J; Staege MS; Kramm C
Cancer Immunol Immunother; 2013 Dec; 62(12):1797-809. PubMed ID: 24129764
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer.
Onishi H; Morisaki T; Kiyota A; Koya N; Tanaka H; Umebayashi M; Katano M
Cancer Immunol Immunother; 2013 Jun; 62(6):1029-39. PubMed ID: 23591983
[TBL] [Abstract][Full Text] [Related]
17. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.
Imai C; Iwamoto S; Campana D
Blood; 2005 Jul; 106(1):376-83. PubMed ID: 15755898
[TBL] [Abstract][Full Text] [Related]
18. γδ T cell and other immune cells crosstalk in cellular immunity.
He Y; Wu K; Hu Y; Sheng L; Tie R; Wang B; Huang H
J Immunol Res; 2014; 2014():960252. PubMed ID: 24741636
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive image-based cytometry for high throughput NK cell cytolysis analysis.
Patel RS; Lucas J; Timmins LM; Mukundan S; Teryek M; Bhatt R; Beaulieu A; Parekkadan B
J Immunol Methods; 2021 Apr; 491():112992. PubMed ID: 33577777
[TBL] [Abstract][Full Text] [Related]
20. Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
Skinner CC; McMichael EL; Jaime-Ramirez AC; Abrams ZB; Lee RJ; Carson WE
Melanoma Res; 2016 Aug; 26(4):329-37. PubMed ID: 27035691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
